EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

Core Insights - EyePoint Pharmaceuticals is focused on developing DURAVYU™ (vorolanib intravitreal insert), an investigational sustained-release therapy aimed at treating VEGF-mediated retinal diseases [1][4][5] - The company announced positive results from the Phase 2 DAVIO 2 trial for wet AMD, highlighting 12-month topline data [1] - Plans for a pivotal non-inferiority Phase 3 trial for DURAVYU™ in wet AMD have been outlined [1] Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts, dedicated to improving the lives of patients with serious retinal diseases [4] - The company utilizes its proprietary Durasert E™ technology for sustained intraocular drug delivery [4] - The lead product candidate, DURAVYU™, combines vorolanib, a selective tyrosine kinase inhibitor, with Durasert E™ [4] Pipeline and Technology - EyePoint's pipeline includes EYP2301, a TIE-2 agonist, and razuprotafib, both formulated with Durasert E™ to enhance treatment outcomes in retinal diseases [4] - The Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four FDA-approved products [4] Upcoming Events - The company will host an R&D Day on June 26, 2024, featuring presentations and discussions with key opinion leaders [6][7] - The agenda will include insights about EyePoint Pharmaceuticals and its ongoing projects [7]